• Explore /
  • Poster
  • / Masterkey-01: Phase I/II, open-label multicenter study to assess safety, tolerability, pharmacokinetics, and antitumor activity of BDTX-189, an inhibitor of allosteric ErbB mutations, in patients with advanced solid malignancies.

Masterkey-01: Phase I/II, open-label multicenter study to assess safety, tolerability, pharmacokinetics, and antitumor activity of BDTX-189, an inhibitor of allosteric ErbB mutations, in patients with advanced solid malignancies.

Abstract Poster

Authors

Erika Hamilton

Erika Paige Hamilton

Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN

Erika Paige Hamilton , Manish R. Patel , Jordi Rodon , David S. Hong , Alison M. Schram , Pasi A. Janne , Patricia LoRusso , Jasgit C. Sachdev , Sai Hong Ou , Elizabeth A Buck , Matthew O'Connor , Nigel Waters , Karsten Witt , Carl Cook

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

Small Molecules

Clinical Trial Registration Number

NCT04209465

Citation

J Clin Oncol 38: 2020 (suppl; abstr TPS3665)

DOI

10.1200/JCO.2020.38.15_suppl.TPS3665

Abstract #

TPS3665

Poster Bd #

395

Abstract Disclosures

Similar Posters

First Author: Alison M. Schram

First Author: Sarina Anne Piha-Paul

First Author: Todd Michael Bauer

First Author: Andrae L. Vandross